/KVUE
KVUE Stock - Kenvue Inc.
Consumer Defensive|Household & Personal ProductsNYSE
$17.02-0.47%
$0.08 (-0.47%) • Dec 19
62
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.36
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).68
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.98
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+9.1%upside
Target: $18.57
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for KVUE
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$16.85 – $17.19
TARGET (TP)$18.57
STOP LOSS$15.66
RISK/REWARD1:1.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.56
52W High$25.17
52W Low$14.02
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $15.46B | $15.44B | $14.95B | $15.05B | $14.47B |
| Gross Profit | $8.96B | $8.64B | $8.29B | $8.42B | $7.85B |
| Gross Margin | 58.0% | 56.0% | 55.4% | 55.9% | 54.2% |
| Operating Income | $1.84B | $2.51B | $2.67B | $2.92B | $-979,000,000 |
| Net Income | $1.03B | $1.66B | $2.06B | $2.08B | $-879,000,000 |
| Net Margin | 6.7% | 10.8% | 13.8% | 13.8% | -6.1% |
| EPS | $0.54 | $0.90 | $1.08 | $1.10 | $-0.47 |
Company Overview
Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair care, and sun and other care products under the Neutrogena, Aveeno, and OGX brand names. The Essential Health segment offers oral and baby, women's health, and wound care products under the Listerine, Johnson's, Band-Aid, and Stayfree brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey. Kenvue Inc. operates as a subsidiary of Johnson & Johnson.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
8
36%
Hold / Neutral
13
59%
Sell / Underperform
1
5%
Analyst Consensus🔴 Bearish
8 Bullish14 Neutral/Bearish
Price Targets
$25
Average Target
↑ 48.0% Upside
Now
$15
Low
$25
Average
$30
High
Based on 24 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 29th 2025 | Canaccord Genuity | Downgrade | Hold | $15 |
| September 26th 2025 | Rothschild & Co Redburn | Upgrade | Buy | $22 |
| April 10th 2025 | Redburn Atlantic | Initiation | Neutral | $23.5 |
| March 24th 2025 | Evercore ISI | Initiation | In-line | $25 |
| January 6th 2025 | Piper Sandler | Upgrade | Overweight | $26← $21 |
| December 12th 2024 | Deutsche Bank | Downgrade | Hold | $24← $25 |
| September 24th 2024 | Jefferies | Initiation | Buy | $27 |
| September 24th 2024 | RBC Capital Mkts | Downgrade | Sector Perform | $24 |
| May 28th 2024 | Citigroup | Resumed | Neutral | $21 |
| April 11th 2024 | Bernstein | Initiation | Underperform | $18 |
| April 3rd 2024 | William Blair | Initiation | Market Perform | - |
| March 1st 2024 | Goldman | Resumed | Neutral | $20 |
| November 17th 2023 | Piper Sandler | Initiation | Neutral | $20 |
| September 11th 2023 | Deutsche Bank | Upgrade | Buy | $27 |
| September 7th 2023 | Canaccord Genuity | Initiation | Buy | $28 |
Earnings History & Surprises
KVUEBeat Rate
82%
Last 11 quarters
Avg Surprise
+2.5%
EPS vs Estimate
Beats / Misses
9/1
1 met exactly
Latest EPS
$0.28
Q4 2025
EPS Surprise History
Q1 24
+9.5%
$0.31vs$0.28
Q2 24
+10.2%
$0.28vs$0.25
Q3 24
+16.1%
$0.32vs$0.28
Q4 24
+2.8%
$0.28vs$0.27
Q1 25
0.0%
$0.26vs$0.26
Q2 25
+5.5%
$0.24vs$0.23
Q3 25
+2.9%
$0.29vs$0.28
Q4 25
+7.6%
$0.28vs$0.26
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 5, 2026 | $0.22 | — | — | — |
Q4 2025 | Nov 3, 2025 | $0.26 | $0.28 | +7.6% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $0.28 | $0.29 | +2.9% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $0.23 | $0.24 | +5.5% | ✓ BEAT |
Q1 2025 | Feb 6, 2025 | $0.26 | $0.26 | 0.0% | = MET |
Q4 2024 | Nov 7, 2024 | $0.27 | $0.28 | +2.8% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $0.28 | $0.32 | +16.1% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $0.25 | $0.28 | +10.2% | ✓ BEAT |
Q1 2024 | Feb 8, 2024 | $0.28 | $0.31 | +9.5% | ✓ BEAT |
Q4 2023 | Oct 26, 2023 | $0.30 | $0.31 | +3.3% | ✓ BEAT |
Q3 2023 | Jul 20, 2023 | $0.29 | $0.32 | +10.3% | ✓ BEAT |
Q2 2023 | May 3, 2023 | $0.32 | $0.19 | -40.6% | ✗ MISS |
Q1 2023 | Jan 1, 2023 | — | $0.21 | — | — |
Q4 2022 | Oct 2, 2022 | — | $0.34 | — | — |
Q3 2022 | Jul 3, 2022 | — | $0.32 | — | — |
Q1 2022 | Mar 31, 2022 | — | $0.28 | — | — |
Q4 2021 | Dec 31, 2021 | — | $0.22 | — | — |
Latest News
'Kenvue Faces FDA Petition to Remove Benadryl's Active Ingredient'- Bloomberg
📉 NegativeBenzinga•Dec 16, 2025, 09:49 PM
Kenvue Form4 Shows Jeffrey C Smith Bought 6,377,694 Shares At An Average Price Of $17.40/Share
📈 PositiveBenzinga•Dec 15, 2025, 09:08 PM
Key deals this week: Kenvue, Warner Bros. Discovery, Adobe, Workday and more
➖ NeutralSeeking Alpha•Nov 22, 2025, 08:15 PM•Also: , ,
Kenvue gains amid speculation on potential rival bidder
📈 PositiveSeeking Alpha•Nov 21, 2025, 09:10 PM
Kenvue shares are trading lower after a U.S. appeals court questioned the exclusion of expert testimony in lawsuits alleging a link between Tylenol and autism.
📉 NegativeBenzinga•Nov 17, 2025, 08:48 PM
KVUE stock has given up its prior gain. Kenvue shares were trading higher after a Texas judge declined to halt the company's planned shareholder payout amid ongoing litigation over Tylenol safety.
➖ NeutralBenzinga•Nov 17, 2025, 08:06 PM
Two Judges On U.S. Appeals Court Reviewing Dismissal Of Private Lawsuits Over Alleged Tylenol Link To Autism Question At A Hearing Whether Expert Testimony Was Properly Excluded
➖ NeutralBenzinga•Nov 17, 2025, 08:03 PM
Kenvue shares are trading higher after a Texas judge declined to halt the company's planned shareholder payout amid ongoing litigation over Tylenol safety.
📈 PositiveBenzinga•Nov 17, 2025, 06:50 PM
Barclays Maintains Equal-Weight on Kenvue, Raises Price Target to $18
➖ NeutralBenzinga•Nov 10, 2025, 06:47 PM•Also:
'Attorney General Ken Paxton Fights To Stop The Manufacturer Of Tylenol From Fraudulently Paying Dividends To Avoid Facing Justice' - Texas AG
📉 NegativeBenzinga•Nov 6, 2025, 08:29 PM•Also:
Texas Attorney General Ken Paxton Files Motion To Prevent Kenvue From Paying Out November Dividend
📉 NegativeBenzinga•Nov 6, 2025, 05:23 PM
Kenvue could see interest from other suitors - analyst
📈 PositiveSeeking Alpha•Nov 3, 2025, 08:20 PM
'Activist Investors in Kenvue Faced Big Losses. Kimberly-Clark Saved the Day; D.E.
➖ NeutralBenzinga•Nov 3, 2025, 03:37 PM•Also:
Kimberly-Clark is buying Tylenol maker Kenvue at a 46% premium
📈 PositiveDowjones•Nov 3, 2025, 01:33 PM•Also:
Kenvue Affirms FY2025 Adj EPS Guidance of $1.00-$1.05 vs $1.04 Est
➖ NeutralBenzinga•Nov 3, 2025, 01:04 PM
Kimberly-Clark to acquire Kenvue in $48.7 billion deal
📈 PositiveSeeking Alpha•Nov 3, 2025, 12:04 PM•Also:
Kimberly-Clark shares are trading lower after the company announced it will acquire Kenvue in a cash and stock transaction with an enterprise value of approximately $48.7 billion.
📉 NegativeBenzinga•Nov 3, 2025, 11:57 AM•Also:
Kenvue shares are trading higher after Kimberly-Clark announced plans to acquire the company in a cash and stock deal.
📈 PositiveBenzinga•Nov 3, 2025, 11:56 AM•Also:
Kenvue Q3 Adj. EPS $0.28 Beats $0.27 Estimate, Sales $3.764B Miss $3.836B Estimate
➖ NeutralBenzinga•Nov 3, 2025, 11:44 AM
Kimberly-Clark To Acquire Kenvue In Cash And Stock Transaction Valued At Approximately $48.7B Creating Global Health And Wellness Leader With 10 Iconic Billion-Dollar Brands
📈 PositiveBenzinga•Nov 3, 2025, 11:33 AM•Also:
Frequently Asked Questions about KVUE
What is KVUE's current stock price?
Kenvue Inc. (KVUE) is currently trading at $17.02 per share. The stock has moved -0.47% today.
What is the analyst price target for KVUE?
The average analyst price target for KVUE is $18.57, based on 1 analyst.
What sector is Kenvue Inc. in?
Kenvue Inc. operates in the Consumer Defensive sector, specifically within the Household & Personal Products industry. The company is traded on the NYSE exchange.
What is KVUE's market cap?
Kenvue Inc. has a market capitalization of $32.62 billion, making it a large-cap company.
Does KVUE pay dividends?
No, Kenvue Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Consumer Defensive SectorADM
Archer-Daniels-Midland Company
$58.24
Mkt Cap: $28.0B
CHD
Church & Dwight Co., Inc.
$85.08
Mkt Cap: $20.8B
EL
The Estée Lauder Companies Inc.
$108.00
Mkt Cap: $38.9B
HSY
The Hershey Company
$189.26
Mkt Cap: $38.4B
JBS
JBS N.V.
$14.50
Mkt Cap: $32.2B
K
Kellanova
$83.44
Mkt Cap: $29.0B
KDP
Keurig Dr Pepper Inc.
$27.89
Mkt Cap: $37.9B
KHC
The Kraft Heinz Company
$24.51
Mkt Cap: $29.0B
KMB
Kimberly-Clark Corporation
$100.65
Mkt Cap: $33.4B
SYY
Sysco Corporation
$74.49
Mkt Cap: $36.1B
Explore stocks similar to KVUE for comparison